80 results about "Citrulline" patented technology

There is provided a method for diagnosing a subject with early onset muscle atrophy, said method comprising: obtaining a biosample from the subject; and assaying the biosample for one or more biomarkers, said one more biomarkers are taurine, proline, citrulline, trigonelline, thymidine, ornithine, glutamate, L-pyroglutamic acid, creatinine, adenine, nicotinamide, 2-methylhippuric acid, maltol, L-arginine, hypotaurine, L-glutamine, homogentisic acid, methylhistidine, oxoglutaric acid, xanthine, L-carnitine, succinate, or a combination thereof; and identifying the subject with early onset muscle atrophy on the basis of a deviation in the one or more of said one more biomarkers.

A solid supplement composition comprising at least one non-ester nitrate compound and at least one isolated amino acid compound, wherein the at least one isolated amino acid compound is citrulline, wherein the at least one isolated amino acid compound is a separate compound than the at least one non-ester nitrate compound, and wherein the solid supplement composition comprises an amount of nitrate ion (NO3—) that is at least 0.33125 mg.

The invention discloses application of a marker in preparation of a sicca syndrome diagnosis product, and a construction method and equipment of a diagnosis model, and relates to the technical field of sicca syndrome diagnosis. The sicca syndrome marker comprises a ratio of citrulline to arginine. The ratio of citrulline to arginine in serum has a close relationship with sicca syndrome, a diagnostic model developed based on the marker has the technical advantages of high diagnostic specificity, high sensitivity and good accuracy, and the detection method is simple, convenient and reliable and is easy to clinically popularize.

The present invention relates to a Corynebacterium glutamicum mutant strain having increased L-citrulline productivity, and a method of producing L-citrulline using the same. The Corynebacterium glutamicum mutant strain is capable of producing L-citrulline in high yield and high concentration while inhibiting the production of by-products, because the activity of the protein that is expressed by the NCgl2657 gene therein has been weakened or inactivated.

The application provides an arginine deiminase mutant with alkali resistance, and the amino acid sequence of the mutant is SEQ ID NO:3. When L-arginine is used as a substrate to synthesize L-citrulline, the pH value of a reaction system can be as high as pH 11 or higher, and hydrochloric acid neutralization is not needed, so that the cost of product separation and purification and waste water treatment is significantly reduced.

The invention discloses a firming and anti-aging composition containing a Campania acuta bark extract and application of the firming and anti-aging composition, and belongs to the technical field of cosmetics. The firming and anti-aging composition containing the Campanumoea maculata bark extract comprises the following components: the Campanumoea maculata bark extract, a Flos Magnoliae Officinalis extract, a Tremella aurantialba extract and a composite polypeptide, and the composite polypeptide is composed of carnosine, acetyl tetrapeptide-5 and tripeptide-10 citrulline in a mass ratio of 1: (0.4-0.6): (0.2-0.6). Through the synergistic effect of the four components, the firming and anti-aging composition has a good effect of inhibiting the activity of elastase and collagenase.

Provided herein is a methods for monitoring inflammatory disease activity in a subject comprising: (i) obtaining a sample from the subject; and (ii) measuring an autoantibody concentration in the sample using an immunoassay. Optionally, the inflammatory disease is rheumatoid arthritis (RA). Optionally, the autoantibody is an anti-citrullinated vimentin autoantibody (anti-Sa) or an anti-carbamylated protein autoantibody (anti-CarP). Optionally, the autoantibody concentration is correlated to a multi-disease biomarker activity (MBDA) score. Also provided herein are systems and kits for performing the method described herein.

A heart boosting formulation comprises: L-carnitine, alpha-linolenic acid, citrulline, vitamin D3, lycopene, holy basil, cinnamon and beetroot.

To provide a new bitterness masking agent of potassium chloride, and to provide a production method or the like including the masking agent.SOLUTION: The bitterness masking agent of potassium chloride contains Balsam Peru essential oil as an active ingredient. Here, it is preferable to further contain at least one or more selected from the group consisting of arginine, glutamic acid, lysine and citrulline. It is also preferable to further contain at least one selected from the group consisting of acetoin, diacetyl, and 2, 3-pentanedione.SELECTED DRAWING: None

The invention relates to a set of diagnostic markers comprising glutamic acid, glutamine, glycine, tryptophan, proline, threonine, citrulline, aspartic acid, and asparagine, for use in diagnosing breast cancer, and to an in vitro method for diagnosing breast cancer.

The present invention provides an antibody or a conjugated fragment of a citrulline-containing epitope used for the treatment or prevention of diseases associated with the release of extracellular traps from cells, such as neutrophil extracellular trap (NET)-associated pathology (NET-associated pathology) or eosinophil extracellular trap (EET)-associated pathology (EET-associated pathology), and provides a method comprising administering at least one dose of the antibody at a specific concentration. The present invention also provides the method itself. NET-related pathologies include systemic lupus erythematosus (SLE), lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia, asthma, allergic rhinovirus exacerbated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, or wound healing in diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in This includes other NET-related pathologies, such as the health of transplanted organs in vivo or ex vivo.The present invention also relates to wound healing in SLE, lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid antibody syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia asthma, allergic rhinovirus exacerbating asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, thrombotic disease, cardiovascular disease, or diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in vivo or ex vivo The present invention provides pharmaceutical compositions and methods for treating and preventing NET-related pathologies, including other NET-related pathologies such as the health of transplanted organs in vivo. NET-related pathologies include eosinophilic diseases or conditions of the skin, respiratory eosinophilic diseases or conditions, gastrointestinal eosinophilic diseases or conditions, allergic diseases or conditions, or eosinophilic diseases or conditions such as helminthic, fungal, viral or bacterial infections.

The invention provides application of lactobacillus reuteri to improvement of prostatitis and erectile dysfunction. The bacterial strain is lactobacillus reuteri NHNK-2001, the lactobacillus reuteri NHNK-2001 is preserved in the China Center for Type Culture Collection on April 25, 2024, and the preservation number of the lactobacillus reuteri NHNK-2001 is CCTCC (China Center for Type Culture Collection) NO: M 2024800. The NHNK-2001 has the functions of generating L-citrulline, repairing aged vascular endothelial cells, promoting vasodilation, repairing aged prostate cells and reducing prostatitis, and can be used for preparing products for improving prostatitis and erectile dysfunction.

The present invention relates to a gene variant of the transcriptional regulator LysG and a method for producing L-citrulline or L-arginine using same. The gene variant of the transcriptional regulator LysG according to the present invention has protein activity that is altered due to the mutation of one or more bases in the base sequence of a gene encoding the transcriptional regulator LysG, and thus, it is possible to effectively produce L-citrulline or L-arginine from a recombinant microorganism comprising the variant.

A micronutrient composition comprises of several combinations of individual ingredients in forming Mix 11, G12, G13 and core mix formulation. Core mix contains magnesium citrate, alpha-Ketoglutaric acid, L-Citrulline and Taurine. The Mix 11, G12 and G13 contains Magnesium Citrate, Alpha-Ketoglutaric Acid, Niacinamide, L-Glutamine, L-Citrulline, Sodium Pyruvate, Succinic acid, Vitamin B complex, Taurine, L-Cysteine, L-Methionine, L-Ascorbic Acid, Coenzyme Q10 or combination thereof. A method of administering and treating a specific disease which is due to one of an oxidative stress, impaired mitobiogenesis and ATP production in a mammal is disclosed.

The present invention provides an antibody comprising citrulline epitope or a binding fragment thereof for use in the treatment or prevention of a disease associated with release of an extracellular trap from a cell, such as a neutrophil extracellular trap (NET)-associated disease (NET-associated disease) or an eosinophil extracellular trap (EET)-associated disease (EET-associated disease), the method comprises administering at least one dose of an antibody at a specific concentration. The present invention also provides these methods themselves. NET related diseases include systemic lupus erythematosus (SLE), lupus, septicemia, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), sicca syndrome, antiphospholipid syndrome, Behcet's disease, spondylitis, spondyloarthropathy, multi-system atrophy, and the like. Parkinson's disease, Lewy body dementia, asthma, allergic rhinovirus aggravated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulogenic uveitis, granulogenic uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, and the like. Or other NET-related diseases, such as wound healing in diabetic patients, cancer, cancer metastasis, and transplanted organ health in vivo or in vitro. The invention also provides a pharmaceutical composition and a method for treating or preventing NET related diseases. Such as SLE, lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), sicca syndrome, antiphospholipid syndrome, Behcet's disease, spondylitis, spondyloarthropathy, multi-system atrophy, Parkinson's disease, Lewy body dementia, asthma, and the like. Allergic rhinovirus aggravated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulometric uveitis, granulometric uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, thrombotic disease, cardiovascular disease, and the like. Or other NET-related diseases, such as wound healing in diabetic patients, cancer, cancer metastasis, and transplanted organ health in vivo or in vitro. The EET-related diseases include eosinophilic granulocyte diseases or conditions, such as eosinophilic granulocyte diseases or conditions of skin; a respiratory eosinophilic granulocyte disease or condition; gastrointestinal eosinophilic cell diseases or disorders; allergic diseases or conditions; or worm, fungus, virus or bacterial infection.

This invention discloses an anhydrous deoxidizer, comprising, by weight, 10-20 parts of a hydroxyl-terminated polybutadiene-maleic anhydride compound, 10-20 parts of modified zeolite, 15-25 parts of modified silica gel, and 45-55 parts of polyethylene terephthalate. The modified silica gel is prepared from silica gel, sorbitol, bis(3-triethoxysilanepropyl) carbonate, and alumina. The modified zeolite is prepared from zeolite, 1-chloroethylcyclohexyl carbonate, maleimide-L-valine-L-citrulline-p-aminobenzyl alcohol, and N,N-dimethylformamide. The anhydrous deoxidizer provided by this invention exhibits excellent deoxidation performance and efficiency.

The invention discloses a citric acid fentanyl injection and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The formula of the citric acid fentanyl injection comprises an active ingredient citric acid fentanyl, a pH buffering agent, a compound stabilizer, an isoosmotic adjusting agent and solvent water for injection, the compound stabilizer is composed of sodium thiosulfate, citrulline and methyl meglumine, and the sodium thiosulfate, the citrulline and the methyl meglumine cooperate to inhibit degradation of citric acid fentanyl citrate. Through a specific compound stabilizer system and an optimized preparation process, the stability, the dissolution efficiency and the quality uniformity of the injection are remarkably improved, the process steps are clear, parameters are definite, and the injection is suitable for large-scale production and has important clinical value and industrial significance.

An object of the present application is to provide a new composition for promoting ketogenesis. According to the present application, there is provided a composition for promoting ketogenesis containing one or two or more amino acids selected from the group consisting of citrulline, leucine, cysteine, taurine, glutamine and aspartic acid. The composition of the present application can further contain either or both of a medium-chain fatty acid and a medium-chain fatty acid ester.

This application discloses a composition containing palmitoyl tripeptide-5, a skin care product, and its uses. The composition containing palmitoyl tripeptide-5 comprises acetyl tripeptide-30 citrulline and palmitoyl tripeptide-5 in a mass ratio of (1.5-2):2. The composition containing palmitoyl tripeptide-5 can protect the skin through the synergistic effect of acetyl tripeptide-30 citrulline and palmitoyl tripeptide-5.

The present invention provides compositions and dosage forms for enhancing energy and reducing inflammation. In certain embodiments, an energy composition comprises citicoline and paraxanthine in a mass ratio of 10:1 to 1:10, preferably about 1:1, delivered as an oral film, capsule, or liquid; exemplary unit doses deliver about 200–300 mg citicoline and about 200–300 mg paraxanthine. In further embodiments, an anti-inflammatory composition comprises astaxanthin, L‑citrulline, glutathione, luteolin, and palmitoylethanolamide within defined mg ranges. Liposomal and spray‑dried liposomal microparticle formulations, including reconstitution parameters, are provided. The compositions yield synergistic effects relative to individual actives, as quantified by accepted models (e.g., combination index <1). Methods of manufacturing, kits, and methods of improving mental focus, physical performance, and recovery are also described.

The invention relates to anti-wrinkle moisturizing cream containing vitriol and a preparation method of the anti-wrinkle moisturizing cream, and belongs to the technical field of cream, the provided anti-wrinkle moisturizing cream can achieve the dual effects of moisturizing and wrinkle resistance at the same time, replenish moisture for skin, improve the dry state, effectively relieve skin lines and improve the compactness, and the moisturizing effect is good. The anti-wrinkle moisturizing cream provided by the invention is prepared from the following components: hydroxypropyl tetrahydropyrantriol, an active component A, an active component B, polydimethylsiloxane, nicotinamide, lauryl PEG (Polyethylene Glycol)-10 tri (trimethylsiloxy) silyl ethyl polydimethylsiloxane, p-hydroxyacetophenone, 1, 2-hexanediol, tocopheryl acetate and Asian white birch juice, the active component A comprises polyglycerol-3, meadowfoam seed oil and alnus macrophyllus seed oil, and the active component B comprises oleoyl tyrosine and tripeptide-10 citrulline.

The present invention discloses a composition containing tyrosol and amino acids, and its application in enhancing athletic performance and anti-fatigue. The amino acids are citrulline and / or arginine. The supplementation of tyrosol in combination with citrulline and / or arginine can increase the rate of nitric oxide production and extend the duration of nitric oxide activity, promoting vasodilation and blood flow. This, in turn, enhances athletic performance, improves endurance, and combats fatigue.

This invention relates to a specially formulated krill oil soft capsule composition designed to optimize fat energy supply and help reduce and delay lactic acid buildup, suitable for use in the food, nutritional supplement, health product, or sports supplement industries. The composition comprises the following ingredients by weight percentage: taurine (0-20%), sodium bicarbonate (0-20%), β-alanine (0-5%), citrulline malic acid (0-10%), with the balance being krill oil rich in Omega-3 polyunsaturated fatty acids. By rationally combining these ingredients, not only is the role of krill oil in promoting fat as an energy source enhanced, but the generation and clearance of lactic acid during exercise are also effectively managed, thereby supporting more sustained energy output and faster recovery. Furthermore, this invention provides a method for preparing the above composition and its application in improving athletic performance and accelerating recovery. This composition and its preparation method offer a new option for individuals seeking efficient energy management and physical recovery.

A method for enhancing or improving muscle functions and / or improving athletic performance and / or preventing or relieving fatigue and / or increasing or improving a nitric oxide signal or level, comprising: administering a citrulline dipeptide or a salt, ester, and derivative thereof to a subject.

The invention discloses a non-alcoholic fatty liver biomarker composition and application thereof, and belongs to the technical field of non-alcoholic fatty liver detection. The non-alcoholic fatty liver biomarker composition comprises at least two of citric acid, linoleic acid, L-glutamic acid, L-glycine, asparaginic acid, progesterone, testosterone and uric acid, and further, the hepatic fibrosis biomarker further comprises at least one of 2-hydroxyestradiol, L-citrulline, L-procholecin, N-acetyl-L-methionine and flavin. The biomarker composition is stable, the possibility of misdiagnosis and missed diagnosis of diseases is greatly reduced, and compared with a single omics analysis method, the biomarker composition is more suitable for the occurrence and development mechanism of the diseases.

The present invention discloses a composition containing tyrosol and amino acids, and its application in enhancing athletic performance and anti-fatigue. The amino acids are citrulline and / or arginine. The supplementation of tyrosol in combination with citrulline and / or arginine can increase the rate of nitric oxide production and extend the duration of nitric oxide activity, promoting vasodilation and blood flow. This, in turn, enhances athletic performance, improves endurance, and combats fatigue.

The invention discloses a nutritional health-care product for preventing and treating urethral calculus and a preparation method thereof, and belongs to the technical field of health care, the nutritional health-care product comprises modified citric acid chelated magnesium, L-ornithine-L-aspartic acid double salt, L-citrulline, a composite plant extract with a specific ratio, functional dietary fiber and the like. The preparation process comprises the key steps of preparation of modified citric acid chelated magnesium, enzymolysis-ultrasonic synergistic extraction of the composite plant extract, graded mixing, precise forming and the like. The utilization rate of the magnesium element is larger than or equal to 85%, the content of plant active ingredients is remarkably increased, calculus crystallization can be synergistically inhibited, calculus discharging is promoted, metabolism is adjusted, the product storage stability and forming quality are excellent, and the product is suitable for urethral calculus prevention and postoperative rehabilitation.

A solid supplement composition comprising at least one non-ester nitrate compound and at least one isolated amino acid compound, wherein the at least one isolated amino acid compound is citrulline, wherein the at least one isolated amino acid compound is a separate compound than the at least one non-ester nitrate compound, and wherein the solid supplement composition comprises an amount of nitrate ion (NO3—) that is at least 0.05625 mg. A semisolid supplement composition comprising at least one non-ester nitrate compound and at least one isolated amino acid compound, wherein the at least one isolated amino acid compound is citrulline, wherein the at least one isolated amino acid compound is a separate compound than the at least one non-ester nitrate compound, and wherein the semisolid supplement composition comprises an amount of nitrate ion (NO3—) that is at least about 0.05625 mg.

The invention belongs to the field of biochemistry and medicinal chemistry, and particularly relates to a preparation method of a beta-alanine-L-citrulline dipeptide compound or a salt thereof and potential application of the beta-alanine-L-citrulline dipeptide compound or the salt thereof in sports nutrition, cardiovascular disease treatment and medical beauty skin care products and cosmetics. The dipeptide compound shows excellent free radical scavenging activity in an in-vitro anti-oxidation experiment, and the free radical scavenging activity is obviously superior to that of common amino acid. According to the invention, high-purity and high-yield preparation of the dipeptide is realized through optimized solid-phase and liquid-phase synthesis processes, and the preparation method has good industrialization potential. The compound has high oxidation resistance and can be used for developing sports nutrition supplements, cardiovascular treatment drugs and anti-aging functional skin care products.